Adverum Historical Income Statement
| ADVM Stock | USD 6.64 0.19 2.95% |
Historical analysis of Adverum Biotechnologies income statement accounts such as Interest Expense of 3.2 M, Selling General Administrative of 31.8 M or Total Revenue of 2.8 M can show how well Adverum Biotechnologies performed in making a profits. Evaluating Adverum Biotechnologies income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Adverum Biotechnologies's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Adverum Biotechnologies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adverum Biotechnologies is a good buy for the upcoming year.
Adverum |
About Adverum Income Statement Analysis
Adverum Biotechnologies Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Adverum Biotechnologies shareholders. The income statement also shows Adverum investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Adverum Biotechnologies Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Adverum Biotechnologies generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most accounts from Adverum Biotechnologies' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Adverum Biotechnologies current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.At this time, Adverum Biotechnologies' Depreciation And Amortization is very stable compared to the past year. As of the 29th of November 2024, Interest Expense is likely to grow to about 3.2 M, while Total Revenue is likely to drop about 2.8 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 153.6M | 157.1M | 127.6M | 82.0M | Cost Of Revenue | 4.6M | 6.5M | 5.6M | 5.4M |
Adverum Biotechnologies income statement Correlations
Click cells to compare fundamentals
Adverum Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adverum Biotechnologies income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.6M | 4.2M | 4.6M | 6.5M | 5.6M | 5.9M | |
| Selling General Administrative | 28.4M | 44.6M | 64.4M | 57.9M | 49.9M | 31.8M | |
| Total Revenue | 1.6M | 250K | 7.5M | 3.6M | 4.1M | 2.8M | |
| Gross Profit | 250K | (4.2M) | 2.9M | (6.5M) | (2.0M) | (1.9M) | |
| Other Operating Expenses | 68.8M | 118.0M | 153.6M | 157.1M | 127.4M | 82.0M | |
| Operating Income | (68.5M) | (118.0M) | (146.1M) | (157.1M) | (123.8M) | (130.0M) | |
| Ebit | (68.5M) | (116.4M) | (145.5M) | (154.5M) | (118.2M) | (112.3M) | |
| Research Development | 40.4M | 73.3M | 89.2M | 99.3M | 77.7M | 50.2M | |
| Ebitda | (67.0M) | (112.2M) | (140.9M) | (147.9M) | (112.6M) | (107.0M) | |
| Cost Of Revenue | 40.4M | 4.2M | 4.6M | 6.5M | 5.6M | 5.4M | |
| Total Operating Expenses | 68.8M | 118.0M | 153.6M | 157.1M | 127.6M | 82.0M | |
| Income Before Tax | (64.5M) | (116.4M) | (145.5M) | (154.5M) | (118.2M) | (124.2M) | |
| Total Other Income Expense Net | 4.1M | 1.6M | (481K) | 549K | 5.5M | 5.8M | |
| Net Income | (64.5M) | (117.5M) | (145.5M) | (154.5M) | (117.2M) | (123.0M) | |
| Income Tax Expense | 1.4M | 1.1M | 4.4M | 74K | (1.1M) | (1.0M) | |
| Net Income From Continuing Ops | (64.5M) | (117.5M) | (145.5M) | (154.5M) | (117.2M) | (123.0M) | |
| Non Operating Income Net Other | 4.4M | 4.1M | 1.7M | 154K | 177.1K | 168.2K | |
| Net Income Applicable To Common Shares | (64.5M) | (117.5M) | (145.5M) | (154.5M) | (139.1M) | (146.0M) | |
| Reconciled Depreciation | 1.6M | 4.2M | 4.6M | 6.5M | 5.6M | 4.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.